Soleno Therapeutics, Inc.
SLNO
$76.70
-$0.08-0.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -198.23M | -175.85M | -131.16M | -65.41M | -52.03M |
| Total Depreciation and Amortization | 2.00M | 1.99M | 1.97M | 1.96M | 1.96M |
| Total Amortization of Deferred Charges | 8.00K | -- | -- | -- | -- |
| Total Other Non-Cash Items | 109.17M | 98.75M | 72.46M | 20.72M | 14.58M |
| Change in Net Operating Assets | -2.28M | 6.02M | 5.31M | -102.00K | 4.75M |
| Cash from Operations | -89.32M | -69.10M | -51.42M | -42.83M | -30.74M |
| Capital Expenditure | -212.00K | -218.00K | -210.00K | -19.00K | -11.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -87.29M | -225.46M | -231.92M | -236.15M | -115.23M |
| Cash from Investing | -87.50M | -225.68M | -232.13M | -236.17M | -115.24M |
| Total Debt Issued | 49.89M | 49.89M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 165.48M | 163.14M | 279.52M | 316.65M | 180.96M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -62.00K | -- | -- | -- | -- |
| Cash from Financing | 215.31M | 213.03M | 279.52M | 316.65M | 180.96M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 38.48M | -81.75M | -4.02M | 37.66M | 34.97M |